Skarlos D V, Fountzilas G, Pavlidis N, Beer M, Makrantonakis P, Aravantinos G, Pantelakos P, Tsavaris N, Karpasitis N, Kosmidis P
Agii Anargiri Cancer Center, Athens, Greece.
Acta Oncol. 1993;32(1):37-41. doi: 10.3109/02841869309083883.
Fifty-two patients with hormone-independent cancer, who complained of anorexia and of weight loss with at least 10%, received megestrol acetate (MA), 480 mg daily, during 1-21 weeks. Of the 41 patients treated during 4 weeks or longer, 38 experienced weight gain. Monthly subjective evaluation of six parameters using a linear analog self-assessment (LASA) form showed a significant improvement in the patient's rating of appetite, mood, nausea and vomiting, and quality of life; the tumor was progressive in 21, stable in 11 and it regressed in only 9 of these patients. No toxicity was observed; one case of death due to a congestive heart failure remains unexplained. MA at the dose used is a powerful appetite stimulant; it contributes to weight increase and might improve the subjective appreciation of quality of life. MA at lower doses should be compared in a prospective trial to the dose used in this study.
52例激素非依赖性癌症患者，主诉有厌食及体重减轻至少10%，在1至21周期间每日接受480毫克醋酸甲地孕酮（MA）治疗。在4周或更长时间接受治疗的41例患者中，38例体重增加。使用线性模拟自我评估（LASA）表格对六个参数进行每月一次的主观评估显示，患者在食欲、情绪、恶心和呕吐以及生活质量评分方面有显著改善；这些患者中21例肿瘤进展，11例稳定，仅9例肿瘤消退。未观察到毒性反应；1例因充血性心力衰竭死亡的原因不明。所用剂量的MA是一种强效食欲刺激剂；它有助于体重增加，并可能改善对生活质量的主观感受。较低剂量的MA应在前瞻性试验中与本研究中使用的剂量进行比较。
